Scribe Therapeutics, Inc.

Scribe Therapeutics is a biopharmaceutical company developing CRISPR-based genetic medicines designed to treat cardiometabolic diseases and other conditions caused by genetic predisposition. The company uses a molecular engineering approach to create CRISPR therapeutics intended for preventative use and broad patient populations, with partnerships including Sanofi for sickle cell and genomic diseases and Eli Lilly for neurological and neuromuscular diseases.